OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/ALK
Lung Cancer — Non-Small Cell (NSCLC)ALK Clinical Trials
ALK gene fusions — most commonly EML4-ALK — occur in 3–5% of NSCLC and are more prevalent in younger, never-smoking patients. Alectinib and lorlatinib are current first-line standards; sequential ALK inhibitors are used upon acquired resistance. Active trials explore next-generation inhibitors and combinations for lorlatinib-resistant disease.
Top recruiting ALK Lung Cancer — Non-Small Cell (NSCLC) trials
Ranked by phase and US site count. See all 71 trials matched to your profile →
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
OSE Immunotherapeutics
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Eli Lilly and Company
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Summit Therapeutics
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
AstraZeneca
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NovoCure GmbH